Abbott LaboratoriesABT
▲ PositiveCapitalrelevance
Raises full-year adjusted EPS guidance and beats Q2 estimates
Impact on stocks 1
Biotech & Genomic Medicine
Abbott LaboratoriesAbbott Raises Earnings Outlook, Sees Stronger Second Half
Earnings
Abbott Laboratories raised its full-year adjusted earnings guidance and signaled accelerating momentum across key businesses. The company now expects adjusted EPS of $5.45 to $5.60, up from $5.38 to $5.58, after second-quarter adjusted earnings of $1.31 per share beat estimates. CEO Robert Ford said about 80% of the expected second-half lift should come from Nutrition, Electrophysiology, Core Laboratory and Cancer Diagnostics. Management highlighted improving nutrition trends, new electrophysiology launches, steadier diagnostics demand and a larger reimbursement runway in diabetes care. Abbott reaffirmed comparable sales growth guidance of 6.5% to 7.5%.
Abbott LaboratoriesRaises full-year adjusted EPS guidance and beats Q2 estimates